Orion Office REIT Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Orion Office REIT Inc trades at $2.17 (market cap $125.50M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 18.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| ONL | SLS | |
|---|---|---|
Market Cap | $125.50M | $2.27B |
Volume | 303,276 | 4,179,659 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $15.46 |
52-Week Low | $1.93 | $1.39 |
Typical Hold Time | 33 Days | — |
Enterprise Value | $542.43M | $2.14B |
Dividend Yield | 3.64% | — |
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.20, down 3.08% today, with a bearish technical signal. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear attractive with P/S of 0.88 and P/B of 0.2, but negative profitability metrics and high debt levels pose concerns. Recent news highlights strategic portfolio repositioning efforts.
Outlook remains challenging with ongoing revenue declines and negative margins, though deep valuation discounts may attract value investors. Key risks include high leverage, office sector exposure, and sustained profitability challenges. Analyst sentiment is mixed with 50% buy and 50% hold ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →